Longitudinal MRI changes after focal therapy for prostate cancer: cryotherapy vs. microwave tissue coagulation.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
16 patients (17 procedures) who underwent cryotherapy and 33 patients (34 procedures) who received MTC therapy between March 2017 and February 2024.
I · Intervention 중재 / 시술
cryotherapy and 33 patients (34 procedures) who received MTC therapy between March 2017 and February 2024
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] While there are distinct modality-specific differences in MRI characteristics in the early phase after between focal cryotherapy and MTC therapy for localized prostate cancer, late-stage findings converge, primarily reflecting fibrosis. These MRI features can help when monitoring the treatment response and guide appropriate follow-up planning.
[PURPOSE] This study compared the longitudinal changes in multiparametric magnetic resonance imaging (mpMRI) findings following lesion-targeted focal cryotherapy with those after microwave tissue coag
APA
Kozawa N, Yamada K, et al. (2025). Longitudinal MRI changes after focal therapy for prostate cancer: cryotherapy vs. microwave tissue coagulation.. Japanese journal of radiology, 43(11), 1878-1892. https://doi.org/10.1007/s11604-025-01831-4
MLA
Kozawa N, et al.. "Longitudinal MRI changes after focal therapy for prostate cancer: cryotherapy vs. microwave tissue coagulation.." Japanese journal of radiology, vol. 43, no. 11, 2025, pp. 1878-1892.
PMID
40637832 ↗
Abstract 한글 요약
[PURPOSE] This study compared the longitudinal changes in multiparametric magnetic resonance imaging (mpMRI) findings following lesion-targeted focal cryotherapy with those after microwave tissue coagulation (MTC) therapy for localized prostate cancer with the aim of determining their modality-specific imaging characteristics and evolution over time.
[MATERIALS AND METHODS] The study included 16 patients (17 procedures) who underwent cryotherapy and 33 patients (34 procedures) who received MTC therapy between March 2017 and February 2024. Serial mpMRI scans were retrospectively reviewed for treatment-induced signal changes on T1-weighted imaging, T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced magnetic resonance imaging (MRI). Three radiologists independently reviewed the images, and interobserver agreement was evaluated.
[RESULTS] Early post-treatment MRI findings indicated distinct modality-specific patterns. Cryotherapy-treated lesions frequently demonstrated marked T1 hyperintensity, whereas MTC-treated lesions predominantly showed slight hyperintensity. On T2-weighted imaging and diffusion-weighted imaging, cryotherapy-treated lesions were characterized by hyperintensity with a hypointense rim, while MTC therapy was more likely to result in heterogeneous hypointensity. Early rim enhancement was common on dynamic contrast-enhanced MRI following cryotherapy (71.4%) and MTC (83.3%) and resolved by 23 and 41 months, respectively. In the late phase (> 12 months), imaging findings generally progressed toward fibrosis, which was characterized by hypointensity across all sequences without enhancement, although convergence timing varied from patient to patient.
[CONCLUSIONS] While there are distinct modality-specific differences in MRI characteristics in the early phase after between focal cryotherapy and MTC therapy for localized prostate cancer, late-stage findings converge, primarily reflecting fibrosis. These MRI features can help when monitoring the treatment response and guide appropriate follow-up planning.
[MATERIALS AND METHODS] The study included 16 patients (17 procedures) who underwent cryotherapy and 33 patients (34 procedures) who received MTC therapy between March 2017 and February 2024. Serial mpMRI scans were retrospectively reviewed for treatment-induced signal changes on T1-weighted imaging, T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced magnetic resonance imaging (MRI). Three radiologists independently reviewed the images, and interobserver agreement was evaluated.
[RESULTS] Early post-treatment MRI findings indicated distinct modality-specific patterns. Cryotherapy-treated lesions frequently demonstrated marked T1 hyperintensity, whereas MTC-treated lesions predominantly showed slight hyperintensity. On T2-weighted imaging and diffusion-weighted imaging, cryotherapy-treated lesions were characterized by hyperintensity with a hypointense rim, while MTC therapy was more likely to result in heterogeneous hypointensity. Early rim enhancement was common on dynamic contrast-enhanced MRI following cryotherapy (71.4%) and MTC (83.3%) and resolved by 23 and 41 months, respectively. In the late phase (> 12 months), imaging findings generally progressed toward fibrosis, which was characterized by hypointensity across all sequences without enhancement, although convergence timing varied from patient to patient.
[CONCLUSIONS] While there are distinct modality-specific differences in MRI characteristics in the early phase after between focal cryotherapy and MTC therapy for localized prostate cancer, late-stage findings converge, primarily reflecting fibrosis. These MRI features can help when monitoring the treatment response and guide appropriate follow-up planning.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.